Biomunex Pharmaceuticals
PrivateLast Round
VC Round
Sep 30, 2025
Total Funding Raised
$3.5M
Company Overview
Biomunex Pharmaceuticals operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a VC Round in September 2025.
Biomunex Pharmaceuticals is a biopharmaceutical company that specializes in the discovery and development of innovative immuno-therapeutics, including bi- and multi-specific antibodies for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Revenue Share
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Biomunex Pharmaceuticals Comparables
Compare Biomunex Pharmaceuticals with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sino Biopharmaceutical | 78% | |
| Merus N.V. | 76% | |
| TRIO Pharmaceuticals, Inc. | 76% |
For institutional investors. Book with your work email.
Biomunex Pharmaceuticals Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Sep 30, 2025 | ||||
| Grant | Nov 3, 2021 | ||||
| Series A | Feb 16, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Biomunex Pharmaceuticals Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Agence Nationale de la Recherche | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 19, 2026
Monthly visitors increased 83% MoM.
- May 8, 2026
Grew 20% QoQ, from 15 to 18 employees.
For institutional investors. Book with your work email.
Biomunex Pharmaceuticals Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Biomunex Pharmaceuticals's valuation, stock price, and market status.
Is Biomunex Pharmaceuticals a public or private company?
Biomunex Pharmaceuticals is a private company.
What is the current stock price of Biomunex Pharmaceuticals?
Biomunex Pharmaceuticals is a private company, so its shares have no public market price. Caplight tracks Biomunex Pharmaceuticals's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Biomunex Pharmaceuticals worth (valuation)?
Valuation information for Biomunex Pharmaceuticals is not publicly available.
Can I buy Biomunex Pharmaceuticals stock?
Biomunex Pharmaceuticals shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Biomunex Pharmaceuticals's last funding round?
Biomunex Pharmaceuticals's most recent funding round was VC Round on September 30, 2025.
Who are the main investors in Biomunex Pharmaceuticals?
Key investors in Biomunex Pharmaceuticals include Agence Nationale de la Recherche.
Will Biomunex Pharmaceuticals IPO soon?
No public IPO plans have been announced for Biomunex Pharmaceuticals.
How can I track Biomunex Pharmaceuticals secondary market activity?
Caplight tracks bids, offers, and trades in Biomunex Pharmaceuticals's shares on secondary markets.